Biolexis Therapeutics is a privately held biopharmaceutical company committed to developing novel targeted therapeutics.
Biolexis Therapeutics has raised $1.6M in total funding. The most recent round was Convertible Note. The last funding was announced in June 2026.
Biolexis Therapeutics's investors include Clarke Capital Partners.
Biolexis Therapeutics is headquartered in American Fork, United States.
Biolexis Therapeutics is a privately held biopharmaceutical company committed to developing novel targeted therapeutics.
Biolexis Therapeutics is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Biolexis Therapeutics — Funding & Investors." VCBacked, June 3, 2026, https://www.vcbacked.co/company/biolexis-therapeutics. Accessed November 12, 2026.
VCBacked. (2026). Biolexis Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/biolexis-therapeutics
{{cite web |title=Biolexis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/biolexis-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Biolexis Therapeutics? Request a listing update